Publications by authors named "R Kachru"
The day-to-day challenges involved in caring for a child with food allergies can be a significant stress within a family. As the child with a food allergy grows up, developmental changes as well as external influences such as bullying and peer pressure can further influence these stressors. When the child with a food allergy is young, the family may be limited on where they can vacation or go out to restaurants, which can cause tension and frustration within the family.
View Article and Find Full Text PDFAims: Left distal transradial arterial approach (ldTRA) is a new interventional route that spares right radial artery (RRA) for use in haemodialysis and as bypass graft. Vasant Kunj Left dIstal Transradial ArtEry approach (VKLITE) study aimed to assess the feasibility and safety of ldTRA access during coronary angiography (CAG) and percutaneous coronary intervention (PCI).
Methods And Results: Between April 2018 and June 2020, 108 patients were enrolled and underwent CAG ± PCI via ultrasound guided ldTRA.
Article Synopsis
- The ARC004 study explored the long-term effects and various dosing regimens of daily oral immunotherapy with Peanut allergen powder (PTAH) in peanut-allergic children and adolescents, following positive results from the PALISADE trial.
- A total of 358 participants, both those who had continued from the PALISADE trial and new participants, underwent different daily or non-daily dosing strategies, with safety and efficacy being assessed.
- Results indicated that daily dosing led to higher desensitization rates with sustained safety, and the immune response continued to show signs of improvement in participants over the course of the study.
Background: Peanut allergy, for which there are no approved treatment options, affects patients who are at risk for unpredictable and occasionally life-threatening allergic reactions.
Methods: In a phase 3 trial, we screened participants 4 to 55 years of age with peanut allergy for allergic dose-limiting symptoms at a challenge dose of 100 mg or less of peanut protein (approximately one third of a peanut kernel) in a double-blind, placebo-controlled food challenge. Participants with an allergic response were randomly assigned, in a 3:1 ratio, to receive AR101 (a peanut-derived investigational biologic oral immunotherapy drug) or placebo in an escalating-dose program.